NASDAQ:ATOS   Atossa Therapeutics, Inc
Atossa Therapeutics ( ATOS ) said Wednesday it has completed enrollment in part B of its phase 1/2a trial of drug candidate AT-H201 in Australia.

AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease, the clinical-stage drugmaker said. The phase 1/2a trial will enroll 60 healthy participants and moderately-ill hospitalized COVID-19 patients and will be carried out in four parts.

Atossa Therapeutics said it completed in vitro testing of AT-H201 in May 2020. Data showed that the components of AT-H201 inhibit COVID-19 infectivity of Vero cells, a type of cell that is being used to study infectivity of the coronavirus.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.